2019
Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy
Ambrosy AP, Stevens SR, Al‐Khalidi H, Rouleau JL, Bouabdallaoui N, Carson PE, Adlbrecht C, Cleland JGF, Dabrowski R, Golba KS, Pina IL, Sueta CA, Roy A, Sopko G, Bonow RO, Velazquez EJ, Investigators O. Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. European Journal Of Heart Failure 2019, 21: 373-381. PMID: 30698316, PMCID: PMC6818499, DOI: 10.1002/ejhf.1404.Peer-Reviewed Original ResearchConceptsCharlson co-morbidity indexCCI scoreSurgical revascularizationEjection fractionMedical therapySTICH trialHeart failureIschemic cardiomyopathyKansas City Cardiomyopathy QuestionnaireCo-morbidity indexCoronary artery bypassCo-morbid conditionsHealth-related qualityCoronary artery diseaseRisk of deathProportional hazards modelYears of ageTreatment effectsGreater functional limitationsArtery bypassCause mortalityIschemic etiologyArtery diseaseWalk testBaseline confounders
2012
Long-Term Survival of Patients With Ischemic Cardiomyopathy Treated by Coronary Artery Bypass Grafting Versus Medical Therapy
Velazquez EJ, Williams JB, Yow E, Shaw LK, Lee KL, Phillips HR, O'Connor CM, Smith PK, Jones RH. Long-Term Survival of Patients With Ischemic Cardiomyopathy Treated by Coronary Artery Bypass Grafting Versus Medical Therapy. The Annals Of Thoracic Surgery 2012, 93: 523-530. PMID: 22269720, PMCID: PMC3638256, DOI: 10.1016/j.athoracsur.2011.10.064.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiac CatheterizationCardiovascular AgentsComorbidityCoronary Artery BypassDatabases, FactualFemaleFollow-Up StudiesHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedMitral Valve InsufficiencyModels, CardiovascularMyocardial IschemiaNorth CarolinaRetrospective StudiesRisk FactorsStroke VolumeTreatment OutcomeConceptsVentricular ejection fractionCoronary artery diseaseMedical therapyArtery diseaseEjection fractionCanadian Cardiovascular Society class III anginaLeft ventricular ejection fractionRisk-adjusted mortality ratesClass III anginaLeft main diseaseCoronary artery bypassLeft main stenosisLong-term mortalityIschemic heart diseaseTrial entry criteriaAcute myocardial infarctionMain outcome measuresPropensity score analysisArtery bypassCohort studyMain stenosisObservational cohortSurvival benefitCardiac catheterizationDuke Databank
2007
The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial
Velazquez EJ, Lee KL, O’Connor C, Oh JK, Bonow RO, Pohost GM, Feldman AM, Mark DB, Panza JA, Sopko G, Rouleau JL, Jones RH, Investigators S. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. Journal Of Thoracic And Cardiovascular Surgery 2007, 134: 1540-1547.e4. PMID: 18023680, PMCID: PMC3638867, DOI: 10.1016/j.jtcvs.2007.05.069.Peer-Reviewed Original ResearchConceptsIschemic Heart Failure (STICH) trialCoronary artery bypassHeart Failure TrialSurgical ventricular reconstructionArtery bypassMedical therapySurgical treatmentFailure TrialVentricular reconstructionPrimary outcomeNormal left ventricular sizeIntensive medical therapyLeft ventricular dysfunctionVentricular ejection fractionCoronary artery diseaseLeft ventricular sizeLong-term survivalQuality of lifeLeft ventricular volumeCardiac causesSubsequent hospitalizationVentricular dysfunctionArtery diseaseEjection fractionHeart failure